Cargando…
A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency
Genotoxic drugs constitute a major treatment modality for human cancers; however, cancer cells' intrinsic DNA repair capability often increases the threshold of lethality and renders these drugs ineffective. The emerging roles of HDACs in DNA repair provide new opportunities for improving tradi...
Autores principales: | Liu, Chuan, Ding, Hongyu, Li, Xiaoxi, Pallasch, Christian P, Hong, Liya, Guo, Dianwu, Chen, Yi, Wang, Difei, Wang, Wei, Wang, Yajie, Hemann, Michael T, Jiang, Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403045/ https://www.ncbi.nlm.nih.gov/pubmed/25759362 http://dx.doi.org/10.15252/emmm.201404580 |
Ejemplares similares
-
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018) -
Signal stability of Cy3 and Cy5 on antibody microarrays
por: Gu, Qiang, et al.
Publicado: (2006) -
Anticancer metallohelices: nanomolar potency and high selectivity
por: Kaner, Rebecca A., et al.
Publicado: (2016) -
CyTOF(®) for the Masses
por: Iyer, Akshay, et al.
Publicado: (2022) -
Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells
por: Chen, Yujuan, et al.
Publicado: (2017)